SCHEMBL18508350

SCHEMBL18508350

CN(C)c1ccc([N+](=O)[O-])c(Sc2ccccc2)n1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TXNRD1 Q16881 4/20 0.51
MAPT P10636 6/20 0.45
GSTP1 P09211 1/20 0.44
GSTM2 P28161 1/20 0.44
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
PDE7A Q13946 1/20 0.40
PDE7B Q9NP56 1/20 0.40
USP47 Q96K76 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
GAA P10253 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18508409 0.87 IDO1 (0.47) TXNRD1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL18508439 0.86 MEN1 (0.56) TXNRD1MAPTMEN1KMT2ALMNA
SCHEMBL18508408 0.84 MERTK (0.43) TXNRD1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL22205280 0.81 TXNRD1 (0.55) TXNRD1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL22264083 0.80 MEN1 (0.58) TXNRD1MAPTGSTP1GSTM2MEN1
SCHEMBL18508428 0.78 MEN1 (0.51) TXNRD1MAPTGSTP1GSTM2MEN1
SCHEMBL2066899 0.72 TXNRD1 (0.51) TXNRD1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL15472273 0.71 MAPT (0.49) TXNRD1MAPTSMN1; SMN2LMNAALDH1A1
SCHEMBL10415949 0.71 KMT2A (0.75) MAPTGSTP1GSTM2MEN1KMT2A
SCHEMBL18508349 0.70 TXNRD1 (0.69) TXNRD1MAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017027359-A1 PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-02-16 WO disclosed